Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer

Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Sponsor
Alliance for Clinical Trials in Oncology
Status
Completed
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT04600336
This phase II trial compares the effect of oxybutynin versus placebo for reducing hot flashes in men receiving androgen deprivation (hormone) therapy for the treatment of prostate cancer . Androgen deprivation therapy decreases testosterone and other androgens through medications or surgical removal of the testicles. Relative to placebo, low- or high-dose oxybutynin may reduce hot flashes in men receiving androgen deprivation therapy.
Intervention
Oxybutynin Chloride, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Condition
Prostate Carcinoma
Investigators
Bradley J. Stish, MD

See list of participating sites